WP only refers to the company as a Structural Heart Company. I believe the mitral repair interest will be our next exciting area. At the time of the AGM they only had 30 percent of the venture. I would like them to get to 80 percent. No doubt we might be creeping up if we are supplying expensive engineering knowhow. That does not come cheap . If it proves disruptive perhaps they could sell it off to fund the pivotal trial. Or sell the TAVR business and keep the mitral.
AVR Price at posting:
$16.01 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)